Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Medarex, Lonza Sign Collaboration Agreement
Lonza and Medarex have signed an agreement. According to the agreement, Medarex would provide manufacturing services in support of the development and commercialization of Medarex’s pipeline of therapeutic
Lonza and Medarex have signed an agreement. According to the agreement, Medarex would provide manufacturing services in support of the development and commercialization of Medarex’s pipeline of therapeutic
FDA has completed its review of PharmAthene’ proposed development plan for SparVax, a recombinant protective antigen (rPA) anthrax vaccine. In response to amendments to the request for proposal
“Millennium has a strong focus on applications with expert technical sales and support. They are a natural fit for BioTek as we grow in Australasia,” noted Dominic Herring,
Bayer Schering Pharma has submitted a New Drug Application (NDA) to the FDA for a new estradiol-based oral contraceptive (estradiol valerate/dienogest). It seeks approval for the indications oral
Cytheris has received Notice of Allowance from the US Patent and Trademark Office (USPTO), for its patent application IL-7 Drug Substance, Composition, Preparation and Uses, US Patent Application
Marc Grossman has filed a civil lawsuit against the manufacturer of Zicam nasal spray, and the national drugstore chain that sold the product to a New York citizen.
Novartis has received the approval for Rasilez (aliskiren), a high blood pressure medicine, for use in Japan. Rasilez directly inhibits renin, an enzyme that triggers a process leading
AstraZeneca is likely to conduct further development of AZD3480, by initiating phase IIb studies in attention deficit/hyperactivity disorder (ADHD). It has agreed to make a $10 million milestone
Repros has entered into the sixth amendment to its agreement with the National Institutes of Health (NHI), relating to Proellex. The company said that the amendment has revised
Funxional Therapeutics has completed the first phase I study of FX125L, an orally available small molecule which belongs to Broad Spectrum Chemokine Inhibitors (BSCIs). FX125L, an Anti-Inflammatory Drug,